MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414714 | Name: Paclitaxel Ceribate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Paclitaxel Ceribate is a mitotic inhibitor used in cancer chemotherapy.

Chemical Structure

Paclitaxel Ceribate
Paclitaxel Ceribate
CAS#186040-50-6 (ceribate)

Theoretical Analysis

MedKoo Cat#: 414714

Name: Paclitaxel Ceribate

CAS#: 186040-50-6 (ceribate)

Chemical Formula: C51H57NO18

Exact Mass: 971.3576

Molecular Weight: 972.01

Elemental Analysis: C, 63.02; H, 5.91; N, 1.44; O, 29.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
186040-50-6 (ceribate) 33069-62-4 (free base) 263351-82-2 (Poliglumex) Paclitaxel-SMCC 117527-50-1 (Paclitaxel-Succinic acid) Paclitaxel-MVCP
Synonym
Paclitaxel Ceribate; Protaxel
IUPAC/Chemical Name
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4-(((2,3-dihydroxypropoxy)carbonyl)oxy)-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate
InChi Key
HSUDWURBWSUCOB-JPHWUADUSA-N
InChi Code
InChI=1S/C51H57NO18/c1-27-34(67-46(61)39(57)38(30-16-10-7-11-17-30)52-44(59)31-18-12-8-13-19-31)23-51(63)43(69-45(60)32-20-14-9-15-21-32)41-49(6,42(58)40(66-28(2)54)37(27)48(51,4)5)35(68-47(62)64-25-33(56)24-53)22-36-50(41,26-65-36)70-29(3)55/h7-21,33-36,38-41,43,53,56-57,63H,22-26H2,1-6H3,(H,52,59)/t33?,34-,35-,36+,38-,39+,40+,41-,43-,49+,50-,51+/m0/s1
SMILES Code
CC(O[C@H]1C([C@@]2([C@@H](OC(OCC(CO)O)=O)C[C@H]3OC[C@]3([C@H]2[C@@H]([C@@]4(C[C@@H](C(C)=C1C4(C)C)OC([C@@H]([C@H](c5ccccc5)NC(c6ccccc6)=O)O)=O)O)OC(c7ccccc7)=O)OC(C)=O)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 972.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014 Sep 15;25(18):2677-81. doi: 10.1091/mbc.E14-04-0916. PMID: 25213191; PMCID: PMC4161504. 2: Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019 Jun 13;24:40. doi: 10.1186/s11658-019-0164-y. PMID: 31223315; PMCID: PMC6567594. 3: Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT. Paclitaxel. Profiles Drug Subst Excip Relat Methodol. 2019;44:205-238. doi: 10.1016/bs.podrm.2018.11.001. Epub 2019 Apr 22. PMID: 31029218. 4: Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015 Jul 24;9:3767-77. doi: 10.2147/DDDT.S88023. PMID: 26244011; PMCID: PMC4521678. 5: Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007 Sep;6(5):609-21. doi: 10.1517/14740338.6.5.609. PMID: 17877447. 6: Sofias AM, Dunne M, Storm G, Allen C. The battle of "nano" paclitaxel. Adv Drug Deliv Rev. 2017 Dec 1;122:20-30. doi: 10.1016/j.addr.2017.02.003. Epub 2017 Feb 28. PMID: 28257998. 7: Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother. 2019 Jan;20(1):95-102. doi: 10.1080/14656566.2018.1546290. Epub 2018 Nov 15. PMID: 30439289. 8: Hoyer KA. Paclitaxel. Clin J Oncol Nurs. 2000 Jan-Feb;4(1):51-2. PMID: 10865588. 9: Rodríguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics. 2010 May;11(5):621-3. doi: 10.2217/pgs.10.32. PMID: 20415548. 10: Yang YH, Mao JW, Tan XL. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020 Dec;18(12):890-897. doi: 10.1016/S1875-5364(20)60032-2. PMID: 33357719.